2024 annual financial data

TScan Therapeutics 2024 Net margin

Direct answer

Net margin was -4,527.66%.

Operating income was -134.82M USD and net income was -127.5M USD.
Operating cash flow was -110.82M USD.

Get free TScan Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
2.82M USD
Operating income
-134.82M USD
Net income
-127.5M USD
Operating cash flow
-110.82M USD